沙利度胺联合肝动脉化疗栓塞治疗肝细胞癌的疗效及安全性  

Efficacy and Safety Of Arterial Chemoemblization Plus Thalidomide in Patients with Primary Hepatocellular Carcinoma

作　　者：何建明[1] 黄从云[2] 张小龙 胡可锦[1] 

机构地区：[1]韶关学院医学院附属医院普外科,广东韶关512026 [2]汕头大学医学院附属粤北人民医院肝胆外科,广东韶关512026

出　　处：《医学临床研究》2015年第7期1308-1311,共4页Journal of Clinical Research

摘　　要：【目的】比较单纯肝动脉化疗栓塞和沙利度胺联合肝动脉化疗栓塞对原发性肝细胞癌的临床疗效及不良反应。【方法】以2011年01月至2013年i0月在韶关学院医学院附属医院和汕头大学附属粤北人民医院病理确诊为原发性肝细胞癌68例患者作为研究对象，随机分为两组，观察组34例采用沙利度胺联合肝动脉化疗栓塞，对照组34例单用肝动脉化疗栓塞。两组患者均治疗至少3个周期（每周期28d），治疗结束后对两组疗效、不良反应进行评价，并随访6～31个月。【结果】治疗后观察组客观缓解率和疾病控制率分别为58：8％（20／34）、91．2％（31／34），对照组分别为32．4％（11／34）、67．7％（23／34），两组比较差异有显著性（均P〈0．05）。观察组总生存时间为（21．915±6．154）个月，长于对照组（16．405±5．595）个月，两组比较差异有显著性（P〈0．05）。两组患者均出现1～2度恶心呕吐、嗜睡、周围神经病变及骨髓抑制等不良反应，两组治疗后不良反应的总发生率为观察组85．3％（29／34），对照组为97．1％（33／34），两组比较差异无显著性（P〉0．05）。【结论】沙利度胺联合肝动脉化疗栓塞与单纯肝动脉化疗栓塞比较，能显著提高原发性肝细胞癌患者的客观缓解率和疾病控制率，且毒副反应可控。[Objective] To compare the clinical efficacies and adverse events of arterial chemoemblization alone versus arterial chemoemblization plus thalidomide for primary hepatocellular carcinoma. [Methodsl A total of 68 cases from Affiliated Hospital, Shaoguan University School of Medicine and Affiliated Yuebei People ＂s Hospital; Shantou University from January 2011 to October 2013 were randomly divided into two groups of arterial chemoemblization plus thalidomide （observation, n = 34） and thalidomide alone （control, n = 34） was used. After a treatment course of at least 3 cycles （28 days/cycle）, the clinical efficacies and adverse events were evaluated. [Results] Their clinicopathological characteristics showed insignificant differences before treatment （ P 〉0.05）. After treatment, the values of remission rate （RR） and disease control rate （DCR） were 58.8% and 91.2% in observation group versus 32.4% and 67.7% in control group. The inter-group differences were significant （all P d0.05）. The time to overall survival was longer in observation groups than that in control groups （21. 915±6. 154 vs 16. 405±5. 595 months）. And the inter-group difference was significant （ P d0.05）. The symptoms of nausea, vomiting, drowsiness, peripheral neuropathy and degree I- II myelosuppression became relieved after symptomatic treatment. And the inter-group differences were insignificant （ P 〉0.05）. [Conclusion] Chemoemblization plus thalidomide can improve significantly RR and DCR of primary hepatoeellular carcinoma, And the adverse events are tolerable.

关 键 词：沙立度胺/治疗应用 肝动脉 癌 肝细胞/药物疗法 化学栓塞 治疗性 

分 类 号：R735.7[医药卫生—肿瘤]